Fig. 9.
Effects of srhCD40L administration on the survival of NOD/SCID mice bearing a Burkitt lymphoma line.
NOD/SCID mice received IV inoculations with 5 × 106 Raji cells on day 0. The following day, mice were treated with either 100 μg srhCD40L or PBS as a vehicle control IP daily for 10 days. There were 10 mice per group and animals were monitored for tumor growth, survival, and morbidity. The results are expressed as the percentage of surviving mice at various days after tumor challenge.
